anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aplastic Anemia( AA), is a set of bone marrow hematopoietic dysfunction caused by a variety of causes, with hyperplasia of bone marrow hematopoietic cells to reduce whole blood cells and peripheral blood at the characteristics of clinical main performance for anemia, bleeding and infection. According to the severity of the bone marrow failure and the progress of the clinical course ,it is divided into Severe Aplastic Anemia (SAA) and the Non - Severe Aplastic Anemia (NSAA).Severe Aplastic Anemia can be divided into two categories: Very Severe Aplastic Anemia (VSAA) and Severe Aplastic Anemia (SAA), with the characteristics of rapid progress, refractory, poor prognosis, high mortality .The natural course is six months or so, and most patients die in a year . Hematopoietic stem cell transplantation and immunosuppressive therapy are two main treatment . The former is by far the only possible cure. It is recommended as first-line treatments, if patients have a matched sibling donor. The recommended age limit is 40 years old. But for those who have no sibling donor or patients older than 40 years old, it is recommend the immunosuppressive therapy.

The investigators have already summarized the effectiveness of rabbit antithymocyte immunoglobulin (ATG), cyclophosphamide (Cy) and cyclosporine, A (CsA) and the combination of the umbilical cord blood infusion for SAA/VSAA patients without suitable donor, with short duration, without long-term immunosuppressive therapy history. The total effectiveness rates has improved to 88%, with shorter immunosuppressive maintaining therapy , rapid hematopoietic reconstruction, fewer complications. The aim of this study is to further explore whether this solution can accelerate hematopoietic reconstruction of SAA/VSAA patients and its clinical curative effect and security. This study scheme has been approved by the Jinan military region general hospital medical ethics committee.
A gel tray for holding a medicament to be applied to the teeth and gums of a patient includes a handle and an opposing buckle. In one embodiment, the buckle includes a tongue portion and a retainer strip surrounding the tongue portion so as to define a narrow space between the tongue portion and the retainer strip, the narrow strip having a width less than the thickness of the handle. The handle has a tongue reception groove extending transverse to its length at a position such that the tongue reception groove is engaged by the tongue when the tray is folded. In another embodiment, slotted tabs are interfitted when the tray is folded. The tray may therefore be securely maintained in the folded state. The tray can be combined with or preloaded with a treatment agent such as a gel comprising a pharmaceutically effective amount of at least one agent for treating teeth or gums dispersed in a gel medium consisting essentially of water and an amount of a water dispersible gelling agent sufficient to form a gel. Preferably, the treatment gel comprises an agent such as from 0.05 to 5 wt. % of a soluble fluoride, either in an acidic gel or a neutral. Acidic gels can contain pharmaceutically acceptable, treatment effective amounts of phosphoric acid and hydrofluoric acid, for example. Neutral gels can have pH modifying agents such as sodium hydroxide.
Adult patients with active Inflammatory Bowel Disease (IBD) are eligible for enrollment after obtaining informed consent. Active disease will be defined based on endoscopy with a Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score of 2 or greater for ulcerative colitis, and a Simple Endoscopic Score for Crohn's Disease (SES-CD) of 3 or greater for Crohn's disease.
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-escalation study to assess a range of doses of OnabotulinumtoxinA for the treatment of male participants with PE. Participants will attend a minimum of 6 or 7 clinic visits and also have 1 or 2 telephone visits. Partners will need to attend a clinic visit during the screening period to provide informed consent and to receive training on measurement and recording of the intravaginal ejaculatory latency time (IELT). Participants will be enrolled in cohorts. Within the first 5 cohorts, 8 participants are to receive OnabotulinumtoxinA and 2 participants to receive placebo. For cohort 6, 12 participants will receive OnabotulinumtoxinA and 12 participants will receive placebo. Participants will receive a single treatment of study medication delivered bilaterally to the bulbospongiosus muscle. The initial OnabotulinumtoxinA total dose in this dose escalation study will be 5 U and the maximum OnabotulinumtoxinA total dose will be 100 U. Upon request and if eligible, participants in cohort 6, will have the option to receive a second injection of OnabotulinumtoxinA (Open-label).
BACKGROUND: Chronic kidney disease (CKD) is a significant public health concern, and patient self-management is an effective approach to manage the condition. Mobile applications have been used as tools to assist in improving patient self-management, but their effectiveness in long-term outpatient follow-up management of patients with CKD remains to be validated. This study aimed to investigate whether using a mobile application combined with traditional outpatient follow-up can improve health outcomes of patients with CKD .
METHODS: This retrospective cohort study recruited CKD patients with stage 1-5 who were not receiving renal replacement therapy from a CKD management center. Two groups were established: the APP + outpatient follow-up group and the traditional outpatient follow-up group. Baseline data was collected from January 2015 to December 2019, followed by a three-year long-term follow-up until December 2022. Laboratory data, all-cause mortality, and renal replacement treatment were then collected and compared between the two groups.
RESULTS: 5326 patients were included in the study, including 2492 in the APP + outpatient group and 2834 in the traditional outpatient group. After IPTW virtualization matching, the final matched the APP + outpatient group consisted of 2489 cases (IQR, 33-55) and 2850 (IQR, 33-55) in the traditional outpatient group. By the end of the study, it was observed that the laboratory data of Phosphorus, Sodium, Triglyceride, Hemoglobin showed significant improvements, Furthermore the APP + outpatient group demonstrated superior results compared to the traditional outpatient group (P < .05). And it was observed that there were 34 deaths (1.4%) in the APP + outpatient group and 46 deaths (1.6%) in the traditional outpatient group(P = .49). After matching for renal replacement therapy outcomes, the two groups were found to be comparable (95% CI [0.72-1.08], P = .23), with no significant difference. However, it was noted that the traditional outpatient group had a lower incidence of using temporary catheters during initial hemodialysis (95% CI [8.4-29.8%], P < .001).
CONCLUSION: The development and application of an app combined with outpatient follow-up management can improve patient health outcomes. However, to ensure optimal preparation for kidney replacement therapy, patients in CKD stages 4-5 may require more frequent traditional outpatient follow-ups, and further develop an information-based decision-making support tool for renal replacement therapy.
The recruitment phase of this trial is 3 years. Duration of the trial is 19 years.

All study patients who undergo mandibular distraction will be indicated for surgery following published and accepted protocols of care for mandibular distraction in this specific patient population. There will be no experimental/treatment arms in this study. All patients will undergo standard of care interventions and assessments that would not change if the patient were not to participate in this study. The purpose of this study is to follow multiple surgical outcomes following these standard of care practices. The methods and procedures detailed below follow published and accepted standards of care.
PURPOSE:To obtain a human antibody free from the contamination with a serum-originated antibody using a medium obtained by removing a component having adverse effect to the growth of cell from serum, by culturing a human antibody-producing cell in a medium containing serum treated with an ion exchange resin and treating the culture liquid with an ion exchange resin. CONSTITUTION:A human antibody-producing cell is cultured in a medium for animal cell culture and containing a serum (e.g. equine serum) treated with an ion exchange resin (e.g. CM-Sepharose). The culture liquid is dialyzed with a phosphoric acid buffer solution and subjected to column chromatography using a column packed with an ion exchange resin. The protein adsorbed to the ion exchange resin is eluted with a phosphoric acid buffer solution to separate the produced human antibody.
A process for producing magnetisable dispersions of finely divided particles in water, is new. The particles consist exclusively or primarily of Fe3O4 and/or  psi -Fe2O3, have a size of 5-50 nm and are coated with a monomolecular adsorption layer of an organic substance. The substance is bonded to the particle surface through a functional gp., e.g. a carboxy, sulphonate, sulphate, thiol, phosphate or phosphonate gp., and has \- 1 other functional gp. available for surface-modifying chemical reactions. The process is characterised in that the chemical reactions are performed in such a way that the sedimentation stability is reversibly adjustable by means of pH displacement. The pH is first displaced into the acidic range until no dispersion in the aq. system occurs, the water is then sepd., and the pH is reset to a sufficient value of the polarity and water-solubility of the polar hydrophilic gps.
Provided are glycoprotein NMB (GPNMB)-binding chimeric antigen receptors (CARs). In some embodiments, a CAR of the present disclosure comprises an extracellular GPNMB-binding domain (e.g., a single chain antibody, such as an scFv), a transmembrane domain, and one or more intracellular signaling domains. Nucleic acids and expression constructs encoding such CARs are also provided. Also provided are cells (e.g., immune cells, such as T cells) comprising the nucleic acids and expression constructs. Aspects of the present disclosure further include compositions comprising a population of such cells expressing the GPNMB-binding CAR on their surface, as well as methods of administering such compositions to treat a condition associated with GPNMB expression and/or activity in a subject in need thereof. Non-limiting examples of conditions associated with GPNMB expression and/or activity include cancer (e.g., sarcomas, such as soft tissue sarcomas), neurodegenerative diseases, and the like.
Soil water deficit (WD) significantly impacts plant survival and crop yields. Many gaps remain in our understanding of the synergistic coordination between molecular and ecophysiological responses delaying substantial drought-induced effects on plant growth. To investigate this synergism in tomato leaves, we combined molecular, ecophysiological, and anatomical methods to examine gene expression patterns and physio-anatomical characteristics during a progressing WD experiment. Four sampling points were selected for transcriptomic analysis based on the key ecophysiological responses of the tomato leaves: 4 and 5 days after WD (d-WD), corresponding to 10% and 90% decrease in leaf stomatal conductance; 8 d-WD, the leaf wilting point; and 10 d-WD, when air embolism blocks 12% of the leaf xylem water transport. At 4 d-WD, upregulated genes were mostly linked to ABA-independent responses, with larger-scale ABA-dependent responses occurring at 5 d-WD. At 8 d-WD, we observed an upregulation of heat shock transcription factors, and two days later (10 d-WD), we found a strong upregulation of oxidative stress transcription factors. Finally, we found that young leaves present a stronger dehydration tolerance than mature leaves at the same drought intensity level, presumably because young leaves upregulate genes related to increased callose deposition resulting in limiting water loss to the phloem, and related to increased cell rigidity by modifying cell wall structures. This combined dataset will serve as a framework for future studies that aim to obtain a more holistic WD plant response at the molecular, ecophysiological and anatomical level.
BACKGROUND: Placental accreta spectrum disorders (PAS) are a high-risk group for severe postpartum hemorrhage (SPPH), with the incidence of PAS increasing annually. Given that cesarean section and anterior placenta previa are the primary risk factors for PAS, therefore, our study aims to investigate the predictive value of clinical characteristics and ultrasound indicators for SPPH in patients with anterior placenta previa combined with previous cesarean section, providing a theoretical basis for early prediction of SPPH.
METHODS: A total of 450 patients with anterior placenta previa combined with previous cesarean section were retrospectively analyzed at Shengjing Hospital affiliated with China Medical University between January 2018 and March 2022. Clinical data and ultrasound indicators were collected. Patients were categorized into SPPH (blood loss >2000mL, 182 cases) and non-SPPH (blood loss ≤ 2000mL, 268 cases) groups based on the blood loss within 24 h postpartum. The population was randomly divided into training and validation cohorts at a 7:3 ratio. LASSO and multifactorial logistic regression analyses were utilized to identify independent risk factors for SPPH. Accordingly, a nomogram prediction model was constructed, the predictive performance was assessed using receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA).
RESULTS: Among the 450 patients, 182 experienced SPPH (incidence rate, 40.44%). Preoperative systemic immune-inflammatory index, preoperative D-dimer level, preoperative placenta accreta spectrum ultrasound scoring system (PASUSS) score, and one-step-conservative surgery were identified as independent risk factors for SPPH in patients with anterior placenta previa combined with previous cesarean section. A nomogram was constructed based on these factors. The areas under the ROC curves for the training and validation cohorts were 0.844 (95%CI: 0.801-0.888) and 0.863 (95%CI: 0.803-0.923), respectively. Calibration curves and DCA indicated that this nomogram demonstrated good predictive accuracy.
CONCLUSIONS: This nomogram presents an effective and convenient prediction model for identifying SPPH in patients with anterior placenta previa combined with previous cesarean section. It can guide surgical planning and improve prognosis.
Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality rates. Despite dramatic advancements in surgical techniques and perioperative management, reported morbidity and mortality rates following PD are 41.56% and 2.88%, respectively, which remain unsatisfactory. Postoperative pancreatic fistula (POPF) is the most common and clinically significant complication following PD. Therefore, accurate and timely prediction of POPF after PD is necessary to reduce secondary mortality from serious complications and optimize individual patient treatment decisions. The C-reactive protein-albumin ratio (CAR) is an inflammatory marker calculated by dividing serum CRP levels by albumin levels and has been associated with poor prognosis in sepsis patients. This study aimed to investigate the predictive significance of CAR for POPF.
Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
FIELD: chemical technology. SUBSTANCE: invention proposes method of synthesis and/or purification of clavulanic acid or its pharmaceutically acceptable salts or ethers. Method involves contact of crude clavulanic acid or its labile derivative in organic solvent with amine of the formula (II):   where: R I  - group of the formula  ; R 2 , R 3 , R 4 , R 5  - hydrogen or C 1 -C 6 -alkyl; m = 0-5. Invention relates to also isolation of clavulanic salt formed with amine, conversion of salt to clavulanic acid or its pharmaceutically acceptable salt or ether. Invention proposes also clavulanic acid salt and amine of the formula (II)  . EFFECT: improved method of synthesis. 40 cl
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. It is used in obtaining a recombinant immunologically active protein of growth and differentiation factor 11 (GDF11), which can be used to increase the meat productivity of farm animals and increase their muscle mass by inducing the synthesis of specific autoantibodies to GDF11 blocking its action and, as a result, stimulating growth muscle tissue. A recombinant protein is obtained. The recombinant protein includes GDF11 and a glucan-binding domain. A method for obtaining the target protein on glucan has been developed, which includes binding the protein to a glucan-containing sorbent with the help of affinity interaction, subsequent washing from unbound bacterial proteins and isolation of the target product. Also, an injectable drug based on the specified protein has been obtained, and a method for increasing the muscle mass of farm animals has been proposed including performing subcutaneous or intramuscular injections of the drug.EFFECT: recombinant GDF11 protein that is easily purified and has sufficient immunogenicity against GDF11.4 cl, 6 tbl, 5 ex
First Episode Psychosis (FEP) often represents a time of crisis for young people and their families. Since peak onset occurs during late adolescence and early adulthood, the onset of serious mental health challenges can disrupt plans for education, relationships, and other milestones of independence. Although some psychoses are brief and self-limiting, more often these symptoms portend a potentially chronic and disabling psychiatric disorder such as schizophrenia. FEP can also be acutely dangerous: youth with FEP are far more likely to die in the year following their diagnosis relative to the general population of 16-30 year old's in the United States. Approximately 100,000 youth in the United States experience FEP every year. Young people identified by providers as experiencing FEP often slip through the cracks before they reach appropriate treatment. A review of privately insured adolescents and young adults in the US showed that 62% of young people in the US with FEP filled no outpatient prescriptions, and 41% received no outpatient psychotherapy, in the year following their index diagnosis. Among those who do have an initial encounter with specialized FEP outpatient care, high attrition is a common problem, with 30% of individuals initially enrolled in first episode programs dropping out prior to completing treatment.

Many individuals experiencing psychosis are reluctant to seek mental health treatment due to lack of insight and fear of psychiatric interventions. Young adults may be torn between distress and dissatisfaction relating to their symptoms and functioning, and mistrust of mental health providers and irritation with their parents' concern. Motivational Interviewing (MI) techniques are designed to elicit this ambivalence through nonjudgmental listening, so that discrepancies between current behaviors and ideal outcomes can be explored. Clinician-delivered MI has been identified as effective for enhancing adherence once individuals with psychosis are involved in care, and may also be useful for engaging those who are not yet interested in treatment. Several studies have found positive results in training and deploying non-professionals to use MI to influence others' health behaviors. MI training for parents and concerned significant others (PCSO) is a promising venue through which PCSO can specifically influence their loved one's decision to seek care and adhere to treatment plans.

MILO is a structured and goal oriented intervention that seeks to accomplish two aims. The primary aim is to facilitate the engagement of IP with evidence-based treatments. The secondary aim is to reduce the distress and increase the wellbeing of PCSO. The intervention will be trialed for feasibility (phase 1, n = 30) and then tested against a small "treatment as usual" (TAU) control arm (phase 2, n = 40). During phase 2, participants will be randomly assigned to either receive MILO (50%) or TAU (50%). The trial will involve a total of 70 participants.
Sodium iodide I-123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid plexus and salivary glands. It is excreted by the kidneys.

The fraction of the administered dose which is accumulated in the thyroid gland may be a measure of thyroid function in the absence of unusually high or low iodine intake or administration of certain drugs which influence iodine accumulation by the thyroid gland. Accordingly, the patient should be questioned carefully regarding previous medications and/or procedures involving radiographic media. Normal subjects can accumulate approximately 10 to 50% of the administered iodine dose in the thyroid gland, however, the normal and abnormal ranges are established by individual physician's criteria. The mapping (imaging) of sodium iodide I-123 distribution in the thyroid gland may provide useful information concerning thyroid anatomy and definition of normal and/or abnormal functioning of tissue within the gland.
Participants will receive subcutaneous (SC) mosunetuzumab plus intravenous (IV) polatuzumab vedotin (M+P). Mosunetuzumab will be administered on Days 1, 8, and 15 of Cycle 1, and thereafter on Day 1 of Cycles 2-8. Polatuzumab vedotin will be administered on Day 1 of each cycle up to Cycle 6. Cycle length = 21 days.
The invention relates to a traditional Chinese medicine composition for treating hypoxic kidney injury diseases, which is prepared from the following raw material medicines in parts by weight: 12 parts of codonopsis pilosula, 12 parts of herba epimedii, 9 parts of processed monkshood, 15 parts of salvia miltiorrhiza, 9 parts of prepared rhubarb, 9 parts of perilla leaf, 12 parts of peach kernel, 6 parts of cordyceps sinensis mycelium, 12 parts of raw cattail pollen, 9 parts of roasted rhizoma cimicifugae and 12 parts of trogopterus dung. The invention also comprises the application of the traditional Chinese medicine composition in preparing a medicine for treating hypoxic kidney injury diseases. Its advantages are: 1. the selected raw material medicines accord with the compatibility principle of 'monarch, minister, assistant and guide', the synergistic effect is achieved, the curative effect is good, and the optimal proportion among the raw material medicines is obtained through experimental screening, so that the Chinese medicinal composition has the advantage of remarkable effect. 2. The medicine of the invention has simple preparation method and wide source of raw material medicines. 3. The invention provides a new treatment scheme for patients suffering from hypoxic kidney injury diseases, improves the survival rate of the patients and has good application prospect.
Plenadren (hydrocortisone modified-release tablet) supplied as 5 mg and 20 mg strengths and administered orally. Plenadren 25 mg will be taken on waking (typically between 06:00 and 08:00 hours).